Table 3.

Incidence of grade ≥3 AEs (%) occurring in ≥5% of HCC patients treated with TKIs [86].

Drug (Reference).	AE Grade ≥3.	Incidence ≥5 (%).
Sorafenib (3).	Diarrhoea.	11.
	Fatigue.	10.
	Abdominal pain.	9.
	HFSR.	8.
	Ascites.	7.
Regorafenib (5).	Hypertension.	15.
	HFSR.	13.
	Increased blood bilirubin.	11.
	Increased AST.	11.
	Fatigue.	9.
	Anaemia.	5..
Lenvatinib (9).	Hypertension.	23.
	Weight loss.	8.
	Increased blood bilirubin.	7.
	Proteinuria.	6.
	Decreased appetite.	5.
	Decreased platelet count.	5.
Cabozantinib (14).	HFSR.	17.
	Hypertension.	16.
	Increased AST.	12.
	Diarrhoea.	10.
	Fatigue.	10.
	Asthenia.	7.
	Decreased appetite.	6.
	Increased ALT.	5.

AE = adverse event; TKI = tyrosine kinase inhibitor; HFSR = hand-foot skin reaction; AST = aspartate transaminase; ALT = alanine aminotransferase.